AR045178A1 - Uso de un componente retinoide seleccionado entre el grupo formado por agentes retinoides activos, precursores de agentes retinoides activos y mezclas de los mismos, para preparar una composicion farmaceutica - Google Patents
Uso de un componente retinoide seleccionado entre el grupo formado por agentes retinoides activos, precursores de agentes retinoides activos y mezclas de los mismos, para preparar una composicion farmaceuticaInfo
- Publication number
- AR045178A1 AR045178A1 ARP040102723A ARP040102723A AR045178A1 AR 045178 A1 AR045178 A1 AR 045178A1 AR P040102723 A ARP040102723 A AR P040102723A AR P040102723 A ARP040102723 A AR P040102723A AR 045178 A1 AR045178 A1 AR 045178A1
- Authority
- AR
- Argentina
- Prior art keywords
- retinoid
- active
- animal
- human
- agents
- Prior art date
Links
- 150000004492 retinoid derivatives Chemical class 0.000 title abstract 11
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 241001465754 Metazoa Species 0.000 abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 208000002874 Acne Vulgaris Diseases 0.000 abstract 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 abstract 1
- 206010000496 acne Diseases 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 229960005280 isotretinoin Drugs 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Uso de un componente retinoide seleccionado entre el grupo formado por agentes retinoides activos, precursores de agentes retinoides activos y mezclas de los mismos, para preparar una composición farmacéutica de aplicación en un método para proveer un efecto terapéutico deseado, tal como tratar acné noduloquístico, a un humana o animal que posee un tracto gastrointestinal, o que posee un peso de cuerpo determinado, en donde dicho método comprende: administrar oralmente a un humano o animal una cantidad terapéuticamente efectiva de dicho componente retinoide, en donde el paso de administración es efectivo para proveer un efecto terapéutico deseado y para proveer una biodisponibilidad más constante del componente retinoide al humano o animal en presencia y ausencia de alimentos en el tracto gastrointestinal del humano o animal con respecto al empleo de isotretinoina el lugar del componente retinoide en un paso de administración oralmente idéntico. Preferentemente, la administración se realiza en forma sistémica para proveer una concentración máxima en sangre de agente retinoide activo en el humano o animal de más de 30 ng/ml, proveyendo un menor efecto secundario o, por lo menos, un efecto secundario reducido con relación al empleo de un agente retinoide de referencia.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49120803P | 2003-07-30 | 2003-07-30 | |
US49114303P | 2003-07-30 | 2003-07-30 | |
US50656103P | 2003-09-26 | 2003-09-26 | |
US51247203P | 2003-10-17 | 2003-10-17 | |
US52556903P | 2003-11-26 | 2003-11-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR045178A1 true AR045178A1 (es) | 2005-10-19 |
Family
ID=34120126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040102723A AR045178A1 (es) | 2003-07-30 | 2004-07-30 | Uso de un componente retinoide seleccionado entre el grupo formado por agentes retinoides activos, precursores de agentes retinoides activos y mezclas de los mismos, para preparar una composicion farmaceutica |
Country Status (7)
Country | Link |
---|---|
US (3) | US20050027003A1 (es) |
EP (1) | EP1653942A1 (es) |
AR (1) | AR045178A1 (es) |
AU (1) | AU2004261301A1 (es) |
CA (1) | CA2534008A1 (es) |
TW (1) | TW200522935A (es) |
WO (1) | WO2005011668A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2013157087A (ru) * | 2011-06-03 | 2015-07-20 | Аллерган, Инк. | Целевая доставка ретиноидных соединений к сальным железам |
EP3126858B1 (en) * | 2014-04-02 | 2022-05-04 | Sikorsky Aircraft Corporation | System and method for health monitoring of electrical systems |
US11135236B2 (en) * | 2018-04-10 | 2021-10-05 | Northwestern University | Retinoic acid receptor gamma agonists to attenuate anthracycline-induced cardiotoxicity |
NO346299B1 (en) | 2019-11-28 | 2022-05-30 | Prores As | Improved tool for remedial of lost circulation while drilling |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4322438A (en) * | 1979-08-06 | 1982-03-30 | United States Of America | Method for the use of orally administered 13-cis-retinoic acid in the treatment of acne |
US5089509A (en) * | 1988-09-15 | 1992-02-18 | Allergan, Inc. | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity |
US5262300A (en) * | 1988-11-30 | 1993-11-16 | The Salk Institute For Biological Studies | Receptors: their identification, characterization, preparation and use |
US5217867A (en) * | 1988-11-30 | 1993-06-08 | The Salk Institute For Biological Studies | Receptors: their identification, characterization, preparation and use |
US5906920A (en) * | 1995-08-29 | 1999-05-25 | The Salk Institute For Biological Studies | Methods for the detection of ligands for retinoid X receptors |
US5776699A (en) * | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
US5958954A (en) * | 1995-09-01 | 1999-09-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US5877207A (en) * | 1996-03-11 | 1999-03-02 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US5919970A (en) * | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
US6248354B1 (en) * | 1999-03-04 | 2001-06-19 | Allergan Sales, Inc. | Capsule system |
-
2004
- 2004-07-29 EP EP04780187A patent/EP1653942A1/en not_active Withdrawn
- 2004-07-29 US US10/901,640 patent/US20050027003A1/en not_active Abandoned
- 2004-07-29 AU AU2004261301A patent/AU2004261301A1/en not_active Abandoned
- 2004-07-29 US US10/902,384 patent/US20050026951A1/en not_active Abandoned
- 2004-07-29 US US10/901,888 patent/US20050026957A1/en not_active Abandoned
- 2004-07-29 CA CA002534008A patent/CA2534008A1/en not_active Abandoned
- 2004-07-29 WO PCT/US2004/025307 patent/WO2005011668A1/en active Application Filing
- 2004-07-30 AR ARP040102723A patent/AR045178A1/es unknown
- 2004-07-30 TW TW093123024A patent/TW200522935A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP1653942A1 (en) | 2006-05-10 |
US20050027003A1 (en) | 2005-02-03 |
US20050026957A1 (en) | 2005-02-03 |
TW200522935A (en) | 2005-07-16 |
AU2004261301A1 (en) | 2005-02-10 |
US20050026951A1 (en) | 2005-02-03 |
WO2005011668A1 (en) | 2005-02-10 |
CA2534008A1 (en) | 2005-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210000761A1 (en) | Topical co-enzyme q10 formulations and treatment of pain, fatigue and wounds | |
ES2703505T3 (es) | Combinación de adapaleno y peróxido de benzoilo para tratar lesiones de acné | |
HK1085390A1 (en) | Solution for ungual and peri-ungual application and its use in preparation of a medicament treating dermatological diseases | |
RU2699651C1 (ru) | Распыляемые носитель и композиция для местного применения, содержащие фосфатидилхолин | |
AR045783A1 (es) | Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide | |
US20220110860A1 (en) | Transdermal formulations | |
JP2023061951A (ja) | 皮膚障害の処置 | |
AR015744A1 (es) | Uso de dexmedetomidina para sedacion en terapia intensiva | |
US20100015216A1 (en) | Methods and materials for treating acne | |
BR0318343A (pt) | composição tópica para administração transdérmica | |
AR045178A1 (es) | Uso de un componente retinoide seleccionado entre el grupo formado por agentes retinoides activos, precursores de agentes retinoides activos y mezclas de los mismos, para preparar una composicion farmaceutica | |
AU2004281521B2 (en) | Topical compositions comprising telmesteine for treating dermatological disorders | |
WO2015044763A1 (en) | Valerolactam derivatives for dermal/transdermal delivery of molecules | |
AR067320A1 (es) | Composicion farmaceutica que comprende la combinacion de un agente antimicrobiano y un agente antioxidante para el tratamiento de infecciones urinarias | |
US20200146983A1 (en) | Enhanced antibiotic and drug delivery for aqueous topical applications for human and veterinary uses | |
RU2005140963A (ru) | Лечебно-профилактическое средство "эйхлофил", его применение и способ профилактики и лечения заболеваний | |
JP6016085B2 (ja) | 抗真菌外用組成物及び抗真菌外用組成物の適用方法 | |
AR108793A1 (es) | Composiciones que comprenden timolol y un agente antiinflamatorio | |
AR045177A1 (es) | Uso de un compuesto tazaroteno para preparar una composicion farmaceutica de utilidad para tratar acne noduloquistico severo o grave | |
AR114012A1 (es) | Método para proporcionar terapia de celiprolol a un paciente | |
AR114587A1 (es) | Formulaciones de epinefrina en aerosol | |
AR067861A1 (es) | Composicion farmaceutica que comprende la combinacion de un agente anticonvulsivamente y un agente benzodiazepinico, indicada para el control y tratamiento de trastornos convulsivos y sindromes epilepticos | |
KR20170035916A (ko) | 중증 여드름의 치료를 위한 아다팔렌 및 벤조일 퍼옥시드의 조합 | |
AR058509A1 (es) | Compuesto macrolona de eritromicina, su uso para preparar un medicamento y composicion farmaceutica que lo comprende | |
RU2011146671A (ru) | Комбинация для профилактики и лечения эндометритов крупного рогатого скота и ее применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |